We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Akero Therapeutics Inc | NASDAQ:AKRO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.37 | 1.31% | 28.69 | 28.69 | 28.78 | 29.12 | 28.4941 | 28.65 | 35,895 | 15:12:03 |
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH/MASH, a disease without any approved therapies. Akero's lead product candidate, EFX, is currently being evaluated in two ongoing, 96-week Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic NASH/MASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH/MASH (F4 fibrosis, compensated), as well as two Phase 3 clinical trials, the SYNCHRONY Histology study in patients with pre-cirrhotic NASH/MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with NASH/MASH or NAFLD/MASLD. Akero is headquartered in South San Francisco. Visit akerotx.com and follow us on LinkedIn and Twitter for more information.
Investor Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina.tartaglia@sternir.com
Media Contact:Sarah O’Connell732.456.0092soconnell@vergescientific.com
1 Year Akero Therapeutics Chart |
1 Month Akero Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions